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ABSTRACT 
A Cerebral cavernous malformation (CCM) is a specific type of vascular malformation that 
primarily affects the central nervous system and leads to stroke, seizures and focal neurological 
deficits. Unlike their normal counterparts, vascular channels in characteristic CCM lesions are 
mere endothelial-cell sinusoids and they lack normal vessel wall components such as smooth 
muscle, adventitia, and astrocytic foot processes. The absence of these vascular components in 
CCM lesions suggests a dsyregulation of cellular adhesion and migration mechanisms. 
KRIT1 is a gene mutated in a monogenetic, familial form of CCM. Previous work has 
established the KRIT1 protein as a plus-end microtuble associated protein that also binds integrin 
cytoplasmic adhesion protein (ICAP-la). These findings suggest a role for KRIT1 in modulating 
cell shape and cell adhesion properties. Extending on this body of information, the work in this 
manuscript suggests that KRIT1 is involved in the control of cell shape dynamics and that KR1T1 
over-expression results in gene-expression changes involving a wide variety of cytoskeletal and 
cell adhesion proteins. Using fluorescence immunocytochemistry we show first that KRIT1 co¬ 
localizes with the Rho-GTPase Rac at the leading edges of spreading bovine aortic endothelial 
(BAE) cells. Transfection of full-length KRIT1 into CHO cells results in the formation of 
cellular processes that are not present in mock transfections or in transfections using only the C- 
terminal component of KRIT1. Finally, using DNA microarray techniques to compliment the 
findings made by microscopy, we show that over-expression with a full-length GFP-tagged 
KRIT1 protein modulates gene-expression in COS7 cells, disproportionately affecting Actin, Ras- 
related proteins and other genes involved in cell shape dynamics and cell adhesion. Taken 
together, our work suggests novel relationships between KRIT1 and other proteins involved in the 
formation of new vasculature. 
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INTRODUCTION 
A History of Central Nervous System Vascular Malformations 
Vascular channels of the brain and spinal cord are paramount for normal human 
function(l). As such, anatomic and physiologic findings related to the cerebral vascular 
system have been described since the days of Hippocrates(2). These concepts would find 
new meaning through the work of anatomic giants like Galen and Vesalius(3, 4) and, 
subsequently, surgical treatment for cerebral vascular diseases would be provided by the 
founding fathers of neurosurgery. Symptomatic central nervous system vascular diseases 
were first recognized 2,400 years ago by Hippocrates and termed “apoplexy”, a Greek 
word literally meaning “struck down by violence(2).” Recognizing the diverse pathways 
leading to stroke or “apoplexy”, early 19Ih century physicians coined the term 
“sanguineous apoplexy,” a term roughly equivalent to our modern day “hemorrhagic 
stroke(2).” It was not until the mid-1800s that Rudolf Virchow would recognize cerebral 
vascular malformations as a significant cause of hemorrhagic stroke(2). 
Cerebral Vascular Malformations 
Our modern conceptions of cerebral vascular malformations are primarily due to 
the contributions of Cushing, Bailey and Dandy(l). In 1928, Cushing and Bailey 
described their operative experiences with cerebral vascular malformations (CVMs), a 
group of vascular lesions that had been previously classified under the misnomer of 
' 
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“angiomatous tumors.” They described three anatomically distinct CVMs: angioma 
venosum, angioma arteriale and telengiectasias. These descriptions, based largely on 
histopathological findings, are still largely relevant today. 
Although several unique types of CVMs have been discovered, many observers 
agree that they may be uniformly characterized as cerebral vascular harmatomas resulting 
from embryologic vascular dysgenesis(5). Generally, CVMs can be distinguished on the 
basis of a few histopathological findings, namely: a) the type of vascular channel 
involved (arterial or venous); b) the presence or absence of intervening neural 
parenchyma; and c) the presence or absence of direct and abnormal connections between 
arterial and venous vascular systems(5). 
Arterial Venous Malformations 
Arteriovenous malformations (AVMs) are the most widely recognized of the 
CVM family, occurring with a prevalence of nearly 1 in 100 people(l, 6, 7). AVMs are 
distinguished from other CVMs by the presence of direct arterial-venous vascular 
channels and the concomitant absence of an intervening capillary bed(l). Clinical 
manifestations of AVMs can be understood by appreciating their physiology. In AVMs, 
a high pressure arterial system feeds a lower pressure venous system whose vasculature is 
ill-equipped for the high pressure vascular flow(8). Ultimately, the venous channels 
compensate by becoming tortuous and dilated. Unfortunately, these dilated, tortuous 
vessels are prone to enlargement and hemorrhage, leading to the clinical symptoms 
associated with AVMs(8). Rarely, the propensity for AVMs can be inherited(9). 
Hereditary hemorrhagic telengiectasias (HHT), or Osler-Weber-Rendu, affects 1 in 
■ 
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100,000 people and can potentially result in AVMs of the brain, nasal mucosa, lung or 
gastrointestinal system(10, 11). In addition, HHT patients can present with capillary 
telengiectasias (see below) of any organ. Wyburn-Mason syndrome also known as 
Bonnet-Dechaume-Blanc syndrome is another rare familial form of AVM in which 
lesions typically affect the mesencephalon in addition to the retina(12). 
Cerebral Venous Malformations 
Cerebral venous malformations (VMs), also known as “venous angiomas,” or 
“venous caput medusae,” are characterized by grossly enlarged vessels of venous origin 
separated by normal neural parenchymal tissue(l). Although the incidence of VMs in 
post-mortem studies nears 3%, they are low-pressure systems which rarely result in 
hemorrhage and are consequently rarely diagnosed(l). Unlike their counterparts, these 
malformations are functional and provide normal drainage to surrounding neural tissue. 
Non-neural venous malformations can be inherited as part of a syndrome known as 
Venous Malformations, Cutaneous and Mucosal (VMCM1), which result in venous 
malformations affecting the spleen, liver, pancreas and other organs(l). 
Capillary Telengiectasias 
Capillary telengiectasias (CTs) are thought to arise from a failure of fetal cerebral 
capillary involution and are inherited at a rate of 2 per 100,000(1). They appear as 
dilated end-capillaries with normal intervening neural parenchyma. CTs are often found 
in HHT syndromes, commonly arising within the pons(l). 
Cerebral Cavernous Malformations 
Cerebral cavernous malformations are dilated sinusoidal channels without 
intervening neural parenchyma(l). They have been variously described as “cavernous 
- 
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hemangiomas,” “cavernomas” and “cavernous malformations.” Magnetic resonance 
imaging (MRI) autopsy series report a post-mortem prevalence of 0.4-0.5%, although the 
actual rates may be significantly higher(l, 13). A familial form of CCM occurs with 
greater frequency among Hispanics, but this disease can frequently exist among other 
ethnic groups(14). Lesions can be located anywhere in the brain and spinal cord with 
equal probability, but they are most frequently found within the pons and the subcortical 
white matter because of the relatively large tissue densities associated with these 
structures(l). 
Histopathologically, the salient features of CCMs are dilated, tortuous, vascular 
sinusoids composed of a single layer of endothelial cells (Figure 1)(15). Notably absent 
from these structures are smooth muscle, adventitia, astrocytic foot processes and other 
components of normal vessel walls(16). Grossly, these lesions are dark,, multi-lobulated 
and often described as having a “mulberry-like” appearance(l). The luminal pressure in 
these CCMs is usually somewhere between those of arterial and venous pressures, and 
may be dependent on the location of the lesions among other factors(l). 
Treatment of Cerebral Vascular Malformations 
The treatment heuristics for CVMs can be quite complicated(17). Prior to treating 
these lesions, one must first consider their natural history. While AVMs have a moderate 
risk of hemorrhage and usually require treatment, clinically silent venous malformations 
often simply require expectant management. Various other factors such as patient 
symptoms, lesion location and size, lesion location and other considerations must be 
evaluated. Once thorough information has been gleaned, expectant management, 
' 
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Figure 1: Histological features of a Cerebral Cavernous Malformation 
A typical cerebral cavernous malformation showing dilated vascular channels with no 
intervening neural parenchyma. 
Figure 2: Tl-weighted MRI image revealing a cavernous malformation. 
Cavernous malformations are characterized by a lesion of mixed signal intensity (inset, 
arrows), consistent with ongoing hemorrhage. Vascular channels, represented by flow 
voids, are also present. 
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endovascular embolization, microsurgical resection and stereotactic radiosurgery are all 
valid options for treatment^, 17). 
Molecular Features of Cerebral Vascular Malformations 
Molecular Genetics of Cerebral Vascular Malformations 
Early investigations into the nature of cerebral vascular malformations yielded 
three factors that suggested a genetic component for CVMs: a) some individuals display 
multiple CVM lesion that appear early in life; b) certain CVMs were demonstrated to be 
inheritable and c) different types of CVMs can occur simultaneously in the same person, 
suggesting a genetic basis(14). With the advent of polymerase chain reaction (PCR) and 
positional cloning techniques, the molecular genetic features of CVMs are being 
elucidated(18). 
Remarkably, autosomal dominant germline mutations have been associated with 
the inheritance of all four vascular malformations discussed here (AVMs, CCMs, VMs 
and CTs). HHT, in which patients display both AVMs and CTs, is associated with two 
possible genetic loci (HHT1, HHT2). HHT1, located on chromosome 9q34.1(19-21), 
encodes a protein called endoglin (ENG)(22, 23), while HHT2, located on chromosome 
12q 13, encodes a protein known as activin receptor-like kinase 1 (ALK1 )(24-26). 
Venous malformations inherited in an autosomal dominant fashion are caused by a 
mutation in chromosome 9p21, in a region encoding for the endothelial cell promoter 
TIE2(27, 28). Finally, cavernous malformations may be caused by mutations on 
chromosome 7q21 (CCM1), 7pl3 (CCM2), or 3q25-27 (CCM3)(29-31). While CCM1 
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and CCM2 encode the proteins KRIT1 and Malcavernin, respectively, the gene at the 
CCM3 locus is currently unknown(32, 33). 
Molecular and Cellular Biology of Cerebral Cavernous Malformations 
Cerebral vascular malformations are endothelial cell phenotypes, and they likely 
represent aberrations in endothelial cell signaling. With the exception of the newly 
discovered Malcavernin gene associated with the CCM2 locus, the function of each gene 
associated with CVMs has been definitively linked to endothelial cells(34-36). The 
expression of KRIT1 protein, the protein of interest for this thesis, has been linked to 
endothelial cells immunocytochemistry and immunohistochemistry experiments(35). 
Beyond these particulars, little is known about the molecular pathogenesis underlying the 
formation of cavernous malformations. 
The KRIT1 protein was initially discovered through a yeast two-hybrid screen 
looking for binding partners for Krevl (RaplA)(37). KRIT1 consequently stands for 
K revl RaplA Interaction Trapped 1 (KRIT1). RaplA is GTPase with sequence 
homology to the Ras oncogene family(38). In spite of this initial connection between Ras 
homologues and KRIT1, there has been little biological proof linking KRIT1, or CCM 
formation, to a pathogenic mechanism involving Ras homologues. 
Attempts to confirm a phy(39)sical KRIT{-RaplA interaction using KRIT1 as a 
yeast two-hybrid bait have yielded somewhat ambiguous results(40, 41). However, these 
same experiments definitively identified integrin cytoplasmic domain-associated protein 
l-a(ICAP la) as a KRIT1 binding partner. ICAP la is a (3 —integrin binding protein 
which apparently modulates cellular adhesion upon integrin engagement(39). While the 
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consequences of ICAP la-integrin binding remain to be fully elucidated, some 
molecular properties of ICAP la are known. For example, it is known that ICAP 
la binds (3-integrin through its protein tyrosine binding (PTB) domain, a domain that 
may have general significance in the pathogenesis of cavernous malformations(33). 
Since integrins recruit Ras homologues to their downstream signaling mechanisms, the 
discovery of ICAP la potentially bridges the gap between KRIT1 involvement in 
vascular development and its relationship with Ras signaling(42). 
Attempts at elucidating the exact mechanism of KRIT1 action have yielded two 
interesting findings. First, our laboratory showed that KRIT1 is a plus-end microtubule¬ 
binding in bovine aortic endothelial (BAE) cells(34). Secondly, through 
immunocytochemistry experiments, we have also shown that KRIT 1-specific antibodies 
stain arterial microvascular structures more readily than venous structures or large arterial 
structures(36). These two findings set the stage for further investigations into the 
pathogenesis of cavernous malformations. Specifically, they suggest a role for KRIT1 in 
angiogenesis, perhaps by control of the cellular cytoskeleton. 
Recently, Marchuk and colleagues identified the gene responsible for cavernous 
malformations at the CCM2 locus, leaving CCM3 as the only unidentified gene(33). The 
CCM2 gene encodes a protein named Malcavernin, which, like ICAP la, contains a 
putative protein tyrosine binding (PTB) domain(33). Although its biological properties 
are currently unknown, the presence of PTB domain within Malcavernin suggests that 
this protein may also be involved in integrin signaling(39). 
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Rationale for Investigations into the Function of the KRIT1 Protein 
Cavernous malformations are an important cause of hemorrhagic stroke. 
Investigations into CCM lesions with Mendelian patterns of transmission provide an 
opportunity to study single genes which may be generally important in the etiology of 
strokes. By understanding the molecular and cellular properties of the KRIT1 protein, we 
might gain better insight into the pathogenesis of hemorrhagic strokes. 
Since 1999, it has been known that mutations in the KRIT1 gene lead to 
cavernous malformations(32). Yet, besides the discovery that the KRIT1 protein is a 
microtubule-associated protein that also binds ICAP la , little else is known about the 
function of this protein. This dearth of information on the KRIT1 protein has forced us to 
seek new ways of examining the KRIT1 protein. 
The presence of multiple peptide domains within KR1T1 raises the possibility 
that each domain may be studied individually to understand how the domains affect the 
overall function of the KRIT1 protein. We hypothesized that over-expression of KRIT1 
in cells which do not usually express KRIT1 would lead to the observation of KRIT1- 
specific cellular phenotypes. Finally, through the use of DNA microarrary as a tool to 
study gene expression changes in cells over-expressing KR1T1, we hypothesized the 
identification of new genes that may be related to KRIT1 function and CCM 
pathogenesis. 
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METHODS AND MATERIALS 
(DNA microarray hybridization experiments were performed with the assistance of Irina 
Tikhanova and Grahame Gould. All other experiments were performed by the author.) 
Preparation of KRIT1-GFP Constructs. We generated a series of KRIT1 over¬ 
expression constructs fused to the N-terminus of the green fluorescent protein (GFP) 
coding sequence in an EGFP-N3 vector (BD Clontech) for over-expression and 
localization experiments. KRT1 was amplified from mouse brain and human kidney 
DNA libraries (Richard Lifton’s laboratory, Yale School of Medicine). A full-length 
(FL) KRIT1 was amplified by a using a (sense -5’ 
AGCGCAATCTCGAGAAGCCACCATGGGAAATCCAGAAAACATG 3’ antisense 5’ 
AGCGCAAATAAGCTTATGAATTTCTTTCAGAGGGCAT 3’) primer set. An N- 
terminus KRIT1 amplicon was made using a (sense 5’ 
AGCGCAATCTCGAGAAGCCACCATGGGAAATCCAGAAAACATG 3’ and 
antisense 5’ AGCGCAAATAAGCTTAGCTCATGCTTCGCTGCCATTT 3’) primer set. 
The C-terminus KRIT1 amplicon was made using a ( sense 5’ 
AGCGCAATCTCGAGAAGCCACCATGAAATGGCAGCGAAGCATGAGC 3’ and 
antisense 5’ AGCGCAAATAAGCTTATGAATTTCTTTCAGAGGGCAT 3’) primer 
set. The Hispanic mutant KRIT1 sequence which containing a 2105 C-*T mutation was 
constructed using a (sense - 5’ 
AGCGCAATCTCGAGAAGCCACCATGGGAAATCCAGAAAACATG 3’ and 
antisense 5’ AGCGCAATAAGCTTGTTGAGAGAGACGCATTCCTTCCA 3’) primer 
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set. All primers contained internal Kozak consensus sequence (5’ ACCATGG 3’) which 
was incorporated into the sequence of all PCR amplicons. Resultant amplicons and the 
E-GFP N3 vector were digested with restriction enzymes Xho 1 (New England Biolabs, 
Beverly MA) at the 5’ position and Hindlll (New England Biolabs, Beverly MA) at the 
3’ position. Reactions were carried out at 37° C for 1 hour. Constructs were ligated into 
the E-GFP N3 vector using DNA Ligase (New England Biolabs, Beverly MA) at 4° C 
overnight. The ligated mixture was grown in Super Competent E. Coli cells and positive 
colonies were picked. Colonies were grown in LB medium and mini-preps performed 
with a Mini-kit (Qiagen,Valencia CA). DNA obtained from Qiagen kits were sequenced 
(Keck Sequencing Laboratory, Howard Hughes Medical Institute, Yale Medical School) 
and verified using various a GFP ( sense 5’ GCTAGCGCTACCGGACTCAGATCT 3’ 
and various KRIT antisense) primer sets. 
In vitro cell culture. COS7 cells (ATCC, Rockville MD) were generally grown 10cm 
culture dishes with low glucose 10ml Dulbecco’s Modified Eagle Medium (DMEM) 
(GIBCO BRL, Carlsbad CA) supplemented with 10% Fetal Bovine Serum (GIBCO), 
lOmM sodium pyruvate, lOmM HEPES buffer, 100 U mL 1 penicillin, 100 mg mL 1 
streptomycin and 0.25 mg mL 1 amphotericin B. CHOK1 and BAEC cells were grown in 
10ml high glucose Dulbecco’s Modified Eagle Medium (DMEM) (GIBCO BRL, 
Carlsbad CA) supplemented with 10% Fetal Bovine Serum (GIBCO), lOmM sodium 
pyruvate, lOmM HEPES buffer, 100 U mL 1 penicillin, 100 mg mL 1 streptomycin and 
0.25 mg mL 1 amphotericin. Cell culture was maintained by washing cells with PBS 
(Sigma, Saint Louis MO) and treating with lmL 
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Immunocytochemistry. Cells were grown on microscope slides and allowed to grow to 
50-70% confluence. On the day of an experiment, cells were washed with PBS (Sigma) 
and coverslips were removed from Petri dishes and placed into a humid chamber. Cells 
were fixed with 3-5% paraformaldehyde, permeabilized using 0.2% Triton-xlOO and 
blocked with 10% Normal Donkey Serum (Jackson ImmunoLaboratories, West Grove 
PA) and and 1% Bovine Serum Albumin (BSA) in PBS. Cells were incubated with 
primary antibodies using Rac-1 mouse monoclonal (Upstate, Waltham MA), anti- 
vinculin monoclonal (Sigma, Saint Louis MO) or rabbit polyclonal KRIT1 antibodies 
(see Laurans, MSH for characterization). Cells were then incubated with donkey FITC- 
anti rabbit or Cy3 donkey anti-mouse secondary antibodies (Jackson 
ImmunoLaboratories, West Grove PA), washed several times with PBS and then stained 
with DAPI for nuclear staining. For immunocytochemistry experiments with KRIT-GFP 
transfected cells, cells were simply washed with PBS, fixed with paraformaldehyde as 
above and mounted unto slides for fluorescence microscopy. To characterize the length 
of cellular processes, cells were viewed at 40X magnification under the live camera 
microscope (Zeiss). Processes extending from the cell body were measured on the screen 
using a ruler. Counting of cells was begun in the upper left quadrant for slide and 
viewing was conducted in a counter-clockwise direction to insure that cells were not 
duplicated in the count. 
Hybridization of DNA microarray slides. These experiments were performed with the 
help of Irina Tikhanova and Grahame Gould. Microarray experiments reported here were 
all carried out using a 900™ kit from Genisphere (Hatfield PA). Total cellular RNA was 
obtained from KRIT-GFP transfected cells using an RNeasy kit (Qiagen, Valencia CA) 
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and characterized for purity by spectrophotometry. Total cellular cDNA was obtained by 
RT-PCR using superscript!! reverse transcriptase (Invitrogen, Carlsbad CA). To reduce 
backround on the micorarray plate, microarrays were pre-hybridized by applying a pre¬ 
hybridization mix heated to 80° C and incubated for 1-2 hours at 50° C. 
Analysis of microarray data. A scanned image of our microarray was imported into the 
GenePix 4.0 folder and loaded unto an appropriate 21,000 gene grid. The gene grid was 
then manually manipulated to fit the microarray image and genes which did not hybridize 
well (i.e. absent signals or uneven signals) were marked and thus considered ineligible 
for analysis. After formatting the grid as described above, an initial round of analysis 
was performed, giving us several thousand discrete data points to consider. To measure 
the intensity of the hybridization in a given channel (Cy3 or Cy5), we used the mean 
value observed for a given fluor at a single gene as the point of analysis. Only genes 
whose mean values were 2X greater than the mean value of all genes included in the 
initial analysis were considered valid (Figure . The degree of over-expression or under¬ 
expression was assessed by considering the median value of the ratio of Cy5/Cy3 
channels. Only genes with a median of ratios two standard deviations greater than the 
average median of ratios were considered as over-expressed. Under-expression was set 
at the same corresponding value, except in the negative direction. 
RT-PCR of KRIT1-GFP RNA. Total cellular RNA from KRIT1-GFP transfected cells 
was obtained using an RNeasy kit (Qiagen, Valencia CA). Total cellular DNA was 
obtained using reverse transcription with Superscript reverse transcriptase (XXX). C- 
terminal KRIT1-GFP, full-length KRIT1-GFP and the Hispanic mutant KRIT1-GFP PCR 
amplicons were obtained using a (sense - 5’ TAGCACAAGGCATATTGGAC 3’ and 
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antisense 5’ GTCTTCAGTTCAAGCCTATC 3’) primer set yielding a 912 bp fragment. 
DNA from N-terminus KRIT1 GFP was amplified using (sense - 5’ 
GTCC A AT AT GCCTT GT GCT A 3’ and antisense GTCCAATATGCCTTGTGCTA) 
primers yielding a 390 bp fragment. PCR products were run on 0.8% agarose gels and 
visualized by addition of Ethidium Bromide. 
Transfection of KRIT-GFP Constructs into COS7 and CHOK1 cell lines. Cells were 
grown to 70% confluence in 10cm cell culture dishes. On the day of transfection, cells 
were washed with IX PBS (Sigma, Saint Louis, MO) and placed in 12ml of Optimem™ 
media (GIBCO) 15 minutes prior to transfection. Transfections were carried out in 10cm 
culture dishes with coverslips placed at the bottom of the dish for future microscopy 
experiments. For each transfection, 15pg of DNA was placed in 1ml of Optimem and 
incubated for 10 minutes. At the same time, 80pl of Lipofectamine 2000 reagent 
(Invitrogen, Carlsbad CA) was placed in a separate vessel and incubated with 1ml of 
Optimem for 10 minutes. The two reactions were mixed, gently tapped, and then 
incubated for 20 minutes prior to addition into a 10cm dish. 4 hours after addition of the 
DNA/Lipofectamine mixture, the media was removed from culture dishes. Cultures 
dishes were washed once with PBS and the normal cell media was replaced. Cells were 
assessed by fluorescent microscopy at 12, 24, 36 and 48 hours for maximum GFP 
expression. 
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RESULTS 
KRIT1-GFP constructs are expressed in COS7 cells. COS7 cellular expression of the 
various KRIT1-GFP constructs was verified by RT-PCR (Figure 6b) or Western blot 
analysis (Figure 6a). COST cells transfected with KRIT1-GFP constructs express KRIT1 
RNA fragments (Figures 6a), whereas COS7 cells transfected with an empty GFP vector 
expresses no such fragment. In addition, cells transfected with a C-terminus KRIT1-GFP 
construct or an N-terminus KRIT1-GFP construct yield anti-GFP antibody bands of the 
expected sizes (Figure 6b). Anti-GFP western blots of cells transfected with an empty 
GFP vector also results in a protein of the expected size (25KDa). 
KRIT1 co-localizes with Racl in BAEC cells grown on fibronectin. Based on prior 
evidence showing KRIT1 interaction with integrin cytoplasmic adhesion protein 1 a 
(ICAP-la,), we wondered if KRIT1 localization was affected by other integrin- 
dependent cellular events. To investigate this hypothesis, BAEC cells coated with 
fibronectin (an integrin-receptor substrate) were grown for 72h and 
immunocytochemistry using KRIT1 antibodies was performed. Fibronectin coating 
resulted in increased cell spreading for all cells viewed. Immunocytochemistry of BAEC 
cells coated with fibronectin showed KRIT1 localization to membrane ruffles and the 
leading edge of the BAEC cell membrane (Figure 3), a pattern of staining which differed 
from our previously observed microtubular staining in non-spreading cells. To further 
characterize these observations, double staining of KRIT1 and Racl (a protein known to 
localize to membrane ruffles in an integrin-dependent manner was perfomed.. Figure 3 
shows co-localization of Racl and KRIT1 in BAEC cells coated with fibronectin. In 
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order to observe the extent of KRIT1 involvement in integrin-dependent cellular 
processes, we wondered if KRIT1 also localized to integrin-dependent focal adhesions 
stained by vinculin. Our results show that while KRIT1 is associated with Racl at 
membrane ruffles and the leading edge of BAEC cells, there is no co-localization of 
KRIT1 in focal adhesions (Figure 4). These results suggest that KRIT1 may be involved 
in some, but not all integrin-dependent changes resulting cellular and cytoskeletal 
morphology. 
Transfection of KRIT1-GFP induces changes in cellular morphology. COS7 cells 
transfected with various KRIT1-GFP constructs were grown for 36-48 hours, when cells 
displayed maximal expression of green fluorescent protein (GFP). Cells were then fixed 
and observed under fluorescent microscopy at 40X magnification (Zeiss fluorescence 
microscope). Our results indicate that transfection of KRIT1-GFP constructs into COS7 
cells results in distinctive changes to cellular morphology (Figure 8). Particularly, the 
presence of the N-terminus KRIT1-GFP induces long, thin cellular processes (Figure 8, 
NT, FL),, whereas transfection GFP vector causes no observed changes to cellular 
morphology (Figure 8, CT), When we measure the number of cellular processes greater 
than 3cm in length (at 40X magnification), we see greater than a 5-fold increase in these 
cell processes when compared to normal GFP controls (Figure 9). Transfection of C- 
terminal KRIT1-GFP resulted what qualitatively observed large cells (Figure 8, CT); 
however, we have not quantified the degree of CT KRIT1-GFP induced cell spreading. 
Overall results suggest that an unknown KRIT1 N-terminus sequence is responsible for 
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causing extensive changes in cellular morphology marked by induction of long, thin 
cellular processes. 
DNA microarray experiments show differential expression of KRIT1-GFP 
transfected cell. After observing changes in the cellular morphology of KRIT1 
transfected COS7 cells, we were eager to determine if differential expression profiles of 
certain genes could be responsible for these observed morphologies. As an initial attempt 
to determine differentially expressed genes in KRIT1 transfected cells, DNA microarray 
hybridization experiments were performed on C-terminal KRIT1-GFP and full length 
KR1T1-GFP transfected cells (Figure 7, Tablel, Table 2). First, our results show that 
transfection of C-terminal KRIT1-GFP induces up-regulation of actin homologues and 
actin-binding proteins suggesting active cytoskeletal restructuring by the KRIT1 C- 
terminus (Table 1). Notably, C-terminal KR1T1-GFP produced more up-regulated than 
down-regulated genes (Figure 10). Transfection of full-length KR1T1-GFP into COS7 
cells induces a distinct modulatory pattern on gene expression where many more genes 
are down regulated than up regulated (Figure 10). Interestingly, full-length KRIT1 
induced the up-regulation of two Ras-related genes and another gene (Thrombospondin 
4) that is known to mediate neurite outgrowth (Table 2). Many of the genes suppressed 
by full length are pro-apoptotic genes, leading to the conjecture that full-length KRIT1 
may be acting as an anti-apoptotic element, an observation made before in our laboratory 
(O. Kayisli, personal correspondence) 
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KRIT1 Rac Merge 
Figure 3: KRIT1 and Rac co-localization in spreading BAEC cells 
BAEC cells were plated at 20% confluence on fibronectin and allowed to spread for 72 
hours. Immunocytochemistry of cells BAEC cells showing KRIT1 (green) and Racl 
(red) co-localization to membrane edges and membrane ruffles. 
KRIT1 Yin Merge 
Figure 4: KRIT1 localizes to membrane edges, but not focal adhesions 
Spreading BAEC cells, as in Figure X were double-stained with KRIT1 and vinculin 
(vin) to assess whether KRIT1 localizes to focal adhesions (stained by vinculin). Our 
results show that KRIT1 (green) and vinculin (red) co-localize to distinct compartments 
of the membrane edge 
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Figure 5: Schematic representation of KRIT1-GFP constructs. 
Normal KRIT1 (a), full-length KRIT1-GFP (b), KRIT-1 C-terminus-GFP (c), and N- 
terminus-KRITl-GFP constructs (d) are shown. Numbers represent amino acid 
sequences of KRIT1 (1-736 amino acids). Red=ankyrin domain; orange=NPXY domain; 
dark blue=FERM domain; green=GFP domain. 
Figure 6: Western blot and RT-PCR of KRIT1 transfected Cos 7 cells. 
Lysates from Cos7 cells transfected with C-terminus KRIT1 (CT), N-terminus KRIT1 
(NT) and a GFP vector (GFP) were obtained and immunoprecipitated with a monoclonal 
anti-GFP antibody. Results from representative experiments show the expected ~75KDa, 
~50KDa and ~25KDa bands that are expected for CT, NT and GFP, respectively. Full- 
length KRIT1 (FL) Western blot (not shown) showed a band of the expected size. RT- 
PCR of lysates from the same transfection showing Cos7 expression of (FL, CT, 
HSP=Hispanic mutant). KRIT1 expression is absent in GFP tranfected cells. 
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Figure 7: Hybridization of DNA from KRIT1-transfected cells to microarray panel 
DNA microarray panel shows adequate hybridization of DNA from KRIT1-transfected 
cells. All parts of the panel are hybridized except for lower left part of the plate 
(excluded from diagnosis). Similar images were obtained for KRIT1 C-terminus 
transfected cells. 
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Figure 8: Fluorescence microscopy images from GFP or KRT1-transfected Cos 7 cells 
(40X magnification) 
COS7 cells were transfected with constructs expressing an empty GFP vector or various 
KRIT1-GFP fusion constructs. Cells were fixed and viewed under a fluorescence 
microscope 48 hours after transfection. A) Representative cells from transfection with 
an empty GFP vector resulted in non-specific cell spreading. B) A similar phenotype 
was found with transfection of the C-terminus KRIT1-GFP template. C-terminus 
KRIT1-GFP transfected cells were qualitatively found to be much broader than all other 
cells. Transfection of the N-terminus of KRIT1, either by using N-terminus KRIT1-GFP 
(NT) or full-length KRITl-GFPconstructs (FL) resulted in the formation of extensive 
cellular process which often made contact with surrounding cells (red arrows). 
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Figure 9: Assessment of cellular processes in cells transfected with KRT1 constructs 
Cellular processes were identified in KRIT1-GFP transfected cells and those processes 
greater than 3 centimeters at 40X magnification (Figure 8) were included in our analysis. 
Full-length KRIT1-GFP (FL), N-terminal KRIT1 GFP (NT), the empty green fluorescent 
protein (GFP) vector and C-terminal KRIT1-GFP (CT) are shown. 
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A B 
KRIT1-GFP transfects 
Scatter plots representing the total number of genes considered for analysis in the KRIT1- 
GFP overexpression experiments. For C-terminal (CT) experiments, 3,217 discrete genes 
met the criteria for consideration. (Mean median of ratios= .975; StdDev=0.78). 
Overexpression with full-length (FL) fragments provided 2,918 valid genes for analysis 
(Mean median of ratios=.831; StdDev=0.82). 
Figure 10: Total number of genes with significantly modulated expression following 
KRIT1-GFP overexpression. 
For C-terminal KRIT1-GFP (1), 42 genes were up-regulated while 7 were down- 
regulated; conversely, full-length microarray experiments (2) produced only 6 up- 
regulated genes and 39 down-regulated genes. 
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Table 1 
Modulation of Gene Expression after C-terminal KRIT1-GFP transfection of COS7 cells 
Gene/Protein Accession No. Degree of change Comments 
Cell shape/ cycle 
Keratin 7 NM 005556 +2.636 Intermediate filament 
Ezrin NM 003379 +2.601 FERM domain family 
Tubulin beta 5 NM 032525 +2.565 Tubulin cytoskeleton 
FU23324 fis AK026977 +2.521 Myosin 10 
Actinin alpha 1 NM 001102 +2.498 Focal adhesions 
Actin gamma 1 NM 001614 +2.452 Actin family 
FLJ32120fis AK056682 +2.439 Actin beta-like 
Cofilin 1 NM 005507 +2.424 Cell differentiation 
LMHX6 NM 014368 +2.416 Actin-binding 
PR01855 NM 018509 +2.404 Flightless homolog 
Transgelin 2 NM 003564 +2.37 Actin-binding 
DKFZp43 AL133645 +2.36 Actin-binding 
Actin beta NM 001101 +2.354 Actin protein 
Adhesion/Matrix 
SLITRK3 NM 014926 +2.848 Slit gene homologue 
COL9A2 NM 001852 +2.638 Fibrillar collagen 
CDH17 NM 004063 +2.565 Cadherin family 
VGF inducible NM 003378 +2.487 Nerve growth factor 
ADAMTS2 NM 014244 -0.244 Metalloproteinase 
Endocvtosis 
TOMM40 homolog NM 006114 +2.743 Mitochondrial 
EPN1 NM 013333 +2.593 Clathrin vesicles 
LAPTMB4 AY057051 +2.432 Fysososmes 
BIN1 NM 004305 +2.414 Clathrin vesicles 
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Table 2 
Modulation of Gene Expression after Full length KRIT1-GFP transfection of COS7 cells 
Gene/Protein Accession No. Degree of change Comments 
Cell shape/angiogenesis 
RHEB NM 005614 +6.209 Ras GTPase 
ADM NM 001124 +3.274 f angionesis 
THBS4 NM 003248 +2.614 t neurites 
DFKZp434D152 AL136835 +2.54 Ras GAP 
TIMP3* NM 000362 -3.8 f angionesis 
MGC11256* NM 024324 -9.43 Fibrillin-like 
LMNB1 NM 005573 -9.52 Nuc. filament 
Apoptosis 
PPP1R15A NM 014330 -2.52 t apoptosis 
CDKN1A (p21) NM 000389 -2.73 t G1 arrest 
C20orfl 9 NM 021158 -2.79 f apoptosis 
HYOU6 NM 006389 -2.85 f in hypoxia 
DDIT3 (GADDI53) NM 004083 -2.78 f apoptosis 
TIMP3* NM 000362 -3.81 G1 regulation 
NAG-1 NM 004684 -5.07 ? apoptosis 
Adhesion/matrix 
MGC11256* NM 024324 -9.43 TG 
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DISCUSSION 
The function of KRIT1 and the exact nature of biological pathways perturbed in 
cavernous malformations remain to be fully elucidated. One conjecture about the 
function of KRIT1, based on the work of several investigators, is that KRIT1 may serve 
as a transducer between (3-integrin and the cellular cytoskeleton(43). In this model, |3- 
integrin engagement with an extracellular matrix substrate (such as fibronectin) would 
lead to appropriate changes to the cellular cytoskeleton. KRIT1 may serve as a direct 
adaptor between the cytoplasmic face of (3—integrin and microtubules. Alternatively, the 
KRIT1 protein may respond to integrin-engagement by binding ICAP la, a protein 
known to bind (3-integrin directly. Whatever the mechanism, these findings provide no 
definitive proof of KRITl’s role in vascular development. 
A recent experiment where investigators generated KRIT1 knockout mice shows 
that homozygous mutants are embryonic lethal and develop a wide variety of vascular 
malformations primarily restricted to the arterial vasculature(35). In addition, these mice 
also show down-regulation of Notch gene expression(35). While this finding establishes 
cavernous malformations as a pure vascular phenotype, the link between these 
phenotypes and their underlying molecular features are currently missing. 
The work in this thesis provides preliminary information on a number of genes 
which may be involved in KRIT1 signaling. Through immunocytochemistry experiments 
on spreading endothelial cells we first show that KRIT1 staining is consistent with the 
staining of Racl, a small Ras-related Rho GTPase which requires integrin engagement to 
translocate to the plasma membrane. From the plasma membrane, Racl recruits a 
number of downstream effectors and has the net effect of modulating the actin 
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cytoskeleton. Although the relationship between KRIT1 and Racl has not been fully 
explored, it is intriguing to suggest that the KRIT1 protein may be part of a coordinated 
response to integrin engagement. Notably we also show here that, KRIT1, like Racl, is 
not present in integrin-dependent focal adhesions(44). This finding may mean that 
KRIT1 is involved in some specific integrin-based signals but not others. One intriguing 
possibility is that this specificity is conferred by the type of extracellular matrix protein 
which binds the integrin receptor. 
The coordinated actions of integrins, Rho-GTPases such as Rac and the actin 
cytoskeleton lead to changes in cell shape and to the exploration of the cellular micro¬ 
environment through the formation of actin-based cellular processes known as filopodia 
and lamellipodia(45). It is therefore interesting that over-expression of full-length KRIT1 
constructs in COS7 cells leads to an increase in the number of cellular processes. While 
the nature of these cellular processes are currently unknown, it would be worthwhile to 
see if they involve active actin remodeling and if Rho-GTPases are required for their 
formation. 
Perhaps the most intriguing of the findings made here are the genes which are 
modulated by over-expression of KRIT1-GFP constructs in our microarray experiments. 
Although these results are preliminary, the nature of the modulated genes deserves some 
discussion. Over-expression of full-length KRIT1 results in the up-regulation of a 
number of interesting genes. One such gene, Ras homologue enriched in brain (RHEB) 
is a Ras homologue which has been implicated in cell growth(46-48). Interestingly, 
RHEB is involved in regulation the TSC1/TSC2 tumor-suppresor complex, a complex of 
genes mutated in tuberous sclerosis(49). Another Ras-related protein, DFKZp434D152, 
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is a putative Ras GTPase activating protein (RAS-GAP); however, its physiologic 
function is less clear than RHEB. Adrenomedullin (ADM), a gene up-regulated by full- 
length KRIT1 expression has been shown to promote vascular proliferation and migration 
and signals through the phosphatidylinositol 3-kinase (PI3K) and Akt(50, 51). Another 
interesting gene up-regulated by full-length KRIT1 over-expression is Thrombospondin 
4, a gene which has been shown to increase neurite outgrowth(52). This finding is 
particularly interesting in the context of full-length KRIT1 induction of cellular 
processes. 
Microarray experiments performed after C-terminal KRIT1 over-expression in 
COS7 cells also reveal some very interesting genes. The C-terminus of KRIT1 includes a 
Band 4.1, Ezrin, Radixin, Moesin (FERM) domain(53). This domain is included in 
several important proteins including the Neurofibromatosis 2 (Nf2) gene product, 
Merlin(54). FERM domain-containing proteins are hypothesized to tether actin 
microfilaments to the plasma membrane(53). This mechanism provides yet another way 
for the cellular cytoskeleton to respond to changes at the cellular plasma membrane. 
Given this context, the genes modulated by C-terminal KRIT1 (CT) over-expression 
appear consistent with the proposed mechanism of KRIT1 action. Ezrin, one of the 
founding members of the FERM domain family is significantly up-regulated after CT 
over-expression in COS7 cells. Ezrin is important in remodeling cortical actin structures 
and the formation of membrane filopodia in a manner dependent of Rho GTPases(55). 
The up-regulation of Ezrin and the presence of a FERM domain with C-terminus 
of KRIT1 suggests that this fragment may be important for re-organizing the actin 
cytoskeleton. Other proteins up-regulated by CT over-expression corroborate this theory. 
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DKFZp43, Transgelin 2 (SM22), and LMHX6 are all proposed actin-binding proteins and 
are up-regulated by CT over-expression(56). Members of the actin protein family, y- 
actin and (3-actin are also up-regulated by CT over-expression. Yet another actin-related 
protein up-regulated by CT over-expression is Actinin a 1, an actin cross-linker which 
modulates actin-based structures such as focal adhesions and membrane ruffles(57). The 
sheer number of actin-related genes up-regulated by CT over-expression suggest that this 
fragment of KRIT1 is involved in the re-structuring of the actin cytoskeleton. Although 
these experiments require confirmation, the results are promising insights into the 
function of the KRIT1 protein. 
Based on our experiments and those of other investigators, a clearer picture of 
KRIT1 function is emerging. Importantly, our microarray experiments intimate that 
KRIT1 may not be a simple molecule that binds microtubules and ICAP la but one that 
may help to co-ordinate the cellular cytoskeleton in response to integrin engagement. In 
response to (3-integrin activation, a wide variety of cellular proteins including Rho 
GTPases, actin-binding proteins and other proteins are activated to produce cellular 
adhesion structures such as focal adhesions and other important structures involved in 
cellular migration(58). These coordinated actions in response to integrin engagement are 
thought to be important for normal vascular development, and it is possible that a full 
explanation of cavernous malformations fits into these signaling pathways(59). 
It is important to acknowledge that our findings were made by using in-vitro cell 
culture experiments. Cell culture is non-physiologic and results gleaned under such 
conditions may be the consequence of condition artifacts. However, we believe that our 
results represent a reasonable start to future investigations into the molecular 
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pathogenesis of cavernous malformations. Proposed experiments for our laboratory 
include verification of our initial microarray results by amplifying our microarray genes 
using DNA from cavernous malformation tissue samples. 
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CONCLUSIONS 
The work in this thesis provides information about in vitro cell culture 
experiments directed at elucidating the function of the KRIT1 gene. The data presented 
within this body of work expands the previous scope of KRIT1 action and suggests that 
KRIT1 regulation of the cellular cytoskeleton may include the actin-based structures in 
addition to previously shown KRIT1 association with microtubules. Localization 
experiments in spreading endothelial cells show co-localization of KRIT1 and Racl a 
protein known to be involved in widespread rearrangement of the actin cytoskeleton. 
Racl is thought to oppose the formation of focal adhesions, a type of integrin-dependent 
adhesion process. Importantly, ICAP la, one of two known KRIT1-binding proteins, has 
also been shown to oppose the formation of focal adhesions. These findings suggest that 
KRIT1, ICAP la, and Racl may be part of a coordinated integrin signaling mechanisms. 
Transfection of KRIT1-GFP constructs lead to interesting cellular phenotypes 
suggesting active rearrangement of the cellular cytoskeleton. Follow-up experiments 
with DNA microarrays corroborate the observations made by microscopy on transfected 
cells. In particular, C-terminal KRIT1-GFP over-expression leads to the up-regulation of 
several actin-related genes, suggesting that this fragment, with its FERM domain, may 
regulate actin microfilaments. Follow-up experiments must be done to confirm the 
results observed in this thesis. 
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